Lexaria Bioscience Corp. (LEXX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-08-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$11.79M

Year ended 2025-08-31

-$7.63M

Trailing 12 months to 2026-05-31

2021-08-31 EBITDA (USD) 2025-08-31

Period ended	EBITDA	Change YoY	Source filing
2025-08-31	-$11.79M	n/m	2025-11-28, From 2024-09-01
2024-08-31	-$5.68M	n/m	2025-11-28, From 2023-09-01
2023-08-31	-$6.39M	n/m	2024-11-26, From 2022-09-01
2022-08-31	-$6.52M	n/c	2023-11-20, From 2021-09-01
2021-08-31	-$5.58M	n/a	2022-11-28, From 2020-09-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Lexaria Bioscience Corp. (LEXX)	2025-08-31	-$11.79M	n/m
Polomar Health Services, Inc. (PMHS)	2025-12-31	-$776.9K	n/m
Hyperion Defi, Inc. (HYPD)	2024-12-31	-$47.61M	n/m
Onconetix, Inc. (ONCO)	2025-12-31	-$17.84M	n/m
Rallybio Corp (RLYB)	2025-12-31	-$32.97M	n/m
Yarrow Bioscience, Inc. (YARW)	2025-12-31	-$29.73M	n/m
Rafael Holdings, Inc. (RFL)	2025-07-31	-$28.87M	n/m
Quantum Cyber N.V. (QUCY)	2025-12-31	-$15.52M	n/m
Lipella Pharmaceuticals Inc. (LIPO)	2024-12-31	-$5.08M	n/m

Compare LEXX, PMHS, HYPD, ONCO side by side · Screen every company in Pharmaceutical Preparations ↗